title: Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
abstract: OBJECTIVE
  Helicobacter pylori (H. pylori) infection is a strong risk factor for the development of gastric cancer. In 2013, the Japanese government approved H. pylori eradication therapy in patients with chronic gastritis as well as peptic ulcer. However, the continuing decline in eradication rates for first-line H. pylori eradication therapies is an urgent problem. In this study, we investigated changes in the first-line eradication rate from 2001 to 2010.
  
  
  METHODS
  Eradication rates for 7-day triple therapy [proton pump inhibitor (rabeprazole 20 mg, lansoprazole 60 mg, or omeprazole 40 mg)+amoxicillin 1500 mg + clarithromycin (CAM) 400 or 800 mg, daily] were collated from 14 hospitals in the Tokyo metropolitan area. The urea breath test was used for the evaluation of eradication. The cut-off value was less than 2.5%.
  
  
  RESULTS
  The yearly eradication rates (intention to treat/per protocol) were 78.5/79.5% (2001, n=242), 71.2%/72.9% (2002, n=208), 67.8%/70.5% (2003, n=183), 75.6%/84.6% (2004, n=131), 56.4%/70.5% (2005, n=114), 70.5%/75.8% (2006, n=271), 67.4%/82.0% (2007, n=135), 64.0%/76.3% (2008, n=261), 60.5%/74.3% (2009, n=329), and 66.5%/78.8% (2010, n=370), respectively. Examination of eradication rates according to CAM dosage revealed an eradication rate of 65.6% (383/584) for CAM 400 mg daily, and 68.5% (1124/1642) for CAM 800 mg daily, with no significant difference seen between dosages.
  
  
  CONCLUSIONS
  In recent years, eradication rates for first-line triple therapy have obviously decreased, but no noticeable decrease has occurred after 2001.
authors.affiliation: Endoscopy Center, Tokyo Medical University, Tokyo, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kawai
authors.forename: Shin'ichi
authors.initials: S
authors.lastname: Takahashi
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Suzuki
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Sasaki
authors.forename: Akihito
authors.initials: A
authors.lastname: Nagahara
authors.forename: Daisuke
authors.initials: D
authors.lastname: Asaoka
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matsuhisa
authors.forename: Tatsuhiro
authors.initials: T
authors.lastname: Masaoaka
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Nishizawa
authors.forename: Masayuki
authors.initials: M
authors.lastname: Suzuki
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Ito
authors.forename: Naoto
authors.initials: N
authors.lastname: Kurihara
authors.forename: Fumio
authors.initials: F
authors.lastname: Omata
authors.forename: Shigeaki
authors.initials: S
authors.lastname: Mizuno
authors.forename: Akira
authors.initials: A
authors.lastname: Torii
authors.forename: Kohei
authors.initials: K
authors.lastname: Kawakami
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Ohkusa
authors.forename: Kengo
authors.initials: K
authors.lastname: Tokunaga
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Mine
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Sakaki
mesh_terms: D000658:Amoxicillin / Q000008:administration & dosage*; D002908:Chronic Disease; D017291:Clarithromycin / Q000008:administration & dosage*; D060740:Disease Eradication / Q000706:statistics & numerical data*; D005260:Female; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control*; D016481:Helicobacter Infections; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D064750:Rabeprazole / Q000008:administration & dosage*; D013997:Time Factors; D014041:Tokyo / Q000453:epidemiology
chemical_list: D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064750:Rabeprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole
keywords: Helicobacter pylori; clarithromycin; eradication rate; proton pump inhibitor; triple therapy